Latest news with #HER2
Yahoo
14-07-2025
- Business
- Yahoo
Alligator Bioscience Comments on Henlius Dosing First Patient in the US in Phase 3 Trial of HLX22 in Gastric Cancer
LUND, SWEDEN / / July 14, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that it has dosed the first patient in the United States in its global Phase 3 clinical trial (NCT06532006) of HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive metastatic gastric and gastroesophageal junction (GEJ) cancer. HLX22 is an anti-HER2 monoclonal antibody being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues. "We are encouraged to see Henlius dose the first patient in the United States in the Phase 3 trial of HLX22, reflecting continued momentum for this promising program in HER2-positive gastric cancer," commented Søren Bregenholt, CEO of Alligator Bioscience. "While Alligator is not directly involved in the development, we follow it closely as it represents an opportunity for meaningful revenue streams from milestones and royalties upon the future approval of HLX22." Under the terms of the agreement, Alligator is entitled to 35% of AbClon's revenue from its sublicense agreement with Henlius. For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 3:00 p.m. CEST on 14 July 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit Attachments Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
09-07-2025
- Health
Olivia Munn reveals mom was diagnosed with breast cancer after her own 2023 diagnosis
Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to Instagram on Wednesday and revealed that her mom was diagnosed with Stage 1 HER2 breast cancer after Munn's own breast cancer diagnosis in 2023. "Going through cancer is really hard," Munn wrote in a statement shared in the post. "But there's something about watching a loved one go through it that is even more heartbreaking." In the statement, Munn wrote that she "urged my mother and sister to take the Breast Cancer Lifetime Risk Assessment test" after receiving her diagnosis in 2023. According to the Susan G. Komen foundation, the test is a tool "often used by health care providers to estimate breast cancer risk." Dr. Jennifer Ashton, former ABC News chief medical correspondent and a board-certified OB-GYN, said in a 2024 interview that the test "helps to provide an actual numerical risk for lifetime risk of breast cancer and breast cancer diagnosis in the next five years." "It is what we use in medicine to stratify a woman's individual risk in a more precise way," Ashton added. According to the American College of Radiology, people with 20% or greater lifetime risk of breast cancer are considered high risk. Munn said that her mother scored 26.2% on the IBIS, or the Tyrer-Cuzick Risk Assessment test, and because of that score, she wanted her mom to get an MRI, which led to learning about her Stage 1 HER2 breast cancer diagnosis. The American Cancer Society describes HER2 as a "protein that helps breast cancer cells grow quickly." "Breast cancer cells with higher than normal levels of HER2 are called HER2-positive," the ACS states. "These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein." Munn said her mom "completed 12 rounds of chemo" after her diagnosis "and will continue monthly Herceptin transfusions this fall." "I spent many nights taking care of my mom when the chemo became too much, wishing I could fight the fight for her, even if only for a day to give her a little break," she continued. "It's no small feat to realize you can't do it for them. To anyone out there who is taking care of someone or has made it their profession to do so, thank you. These fights can feel near impossible without you." Munn said the Tyrer-Cuzick Risk Assessment "saved my life and now my mom's." The Tyrer-Cuzick model, or IBIS, is a type of breast cancer risk calculator. According to the American College of Obstetricians and Gynecologists, this calculator is one of a few options that physicians can use to calculate lifetime risk of breast cancer. "My mom wanted me to tell you that she hopes by sharing her story it will save someone's life," Munn said. "I want to say how proud I am of my mom," she added. "She's handled all of this with bravery and humor while still driving us crazy (just days after her double mastectomy she tried to do laundry and make dinner -- she's insane)." She thanked "the hospital nurses, patient coordinators and staff who have taken care of my mother," as well as her mother's primary care physician and oncologists, before thanking her own doctors as well. Munn previously opened up about her private battle with breast cancer in a 2024 Instagram post. At the time, she revealed she had been diagnosed with Stage 1 aggressive Luminal B breast cancer in April 2023 and underwent a double mastectomy 30 days later. Since then, Munn has been open about her experience, sharing her story to urge other women to get tested and to raise awareness about the disease. "I'm lucky," she said in her 2024 Instagram post about her diagnosis. "We caught it with enough time that I had options. I want the same for any woman who might have to face this one day."
Yahoo
09-07-2025
- Health
- Yahoo
Olivia Munn reveals mom was diagnosed with breast cancer after her own diagnosis
Olivia Munn is opening up about her mom's breast cancer diagnosis. The "Your Friends and Neighbors" star, 45, took to Instagram on Wednesday and revealed that her mom was diagnosed with Stage 1 HER2 breast cancer after Munn's own breast cancer diagnosis in 2023. "Going through cancer is really hard," Munn wrote in a statement shared in the post. "But there's something about watching a loved one go through it that is even more heartbreaking." Olivia Munn speaks out about breast cancer, fertility issues in 1st TV interview since surgeries In the statement, Munn wrote that she "urged my mother and sister to take the Breast Cancer Lifetime Risk Assessment test" after receiving her diagnosis in 2023. According to the Susan G. Komen foundation, the test is a tool "often used by health care providers to estimate breast cancer risk." Dr. Jennifer Ashton, former ABC News chief medical correspondent and a board-certified OB-GYN, said in a 2024 interview that the test "helps to provide an actual numerical risk for lifetime risk of breast cancer and breast cancer diagnosis in the next five years." "It is what we use in medicine to stratify a woman's individual risk in a more precise way," Ashton added. According to the American College of Radiology, people with 20% or greater lifetime risk of breast cancer are considered high risk. Munn said that her mother scored 26.2% on the IBIS, or the Tyrer-Cuzick Risk Assessment test, and because of that score, she wanted her mom to get an MRI, which led to learning about her Stage 1 HER2 breast cancer diagnosis. The American Cancer Society describes HER2 as a "protein that helps breast cancer cells grow quickly." "Breast cancer cells with higher than normal levels of HER2 are called HER2-positive," the ACS states. "These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein." Munn said her mom "completed 12 rounds of chemo" after her diagnosis "and will continue monthly Herceptin transfusions this fall." "I spent many nights taking care of my mom when the chemo became too much, wishing I could fight the fight for her, even if only for a day to give her a little break," she continued. "It's no small feat to realize you can't do it for them. To anyone out there who is taking care of someone or has made it their profession to do so, thank you. These fights can feel near impossible without you." Olivia Munn on how John Mulaney, son Malcolm support her amid cancer battle Munn said the Tyrer-Cuzick Risk Assessment "saved my life and now my mom's." The Tyrer-Cuzick model, or IBIS, is a type of breast cancer risk calculator. According to the American College of Obstetricians and Gynecologists, this calculator is one of a few options that physicians can use to calculate lifetime risk of breast cancer. "My mom wanted me to tell you that she hopes by sharing her story it will save someone's life," Munn said. "I want to say how proud I am of my mom," she added. "She's handled all of this with bravery and humor while still driving us crazy (just days after her double mastectomy she tried to do laundry and make dinner -- she's insane)." She thanked "the hospital nurses, patient coordinators and staff who have taken care of my mother," as well as her mother's primary care physician and oncologists, before thanking her own doctors as well. Munn previously opened up about her private battle with breast cancer in a 2024 Instagram post. At the time, she revealed she had been diagnosed with Stage 1 aggressive Luminal B breast cancer in April 2023 and underwent a double mastectomy 30 days later. Since then, Munn has been open about her experience, sharing her story to urge other women to get tested and to raise awareness about the disease. "I'm lucky," she said in her 2024 Instagram post about her diagnosis. "We caught it with enough time that I had options. I want the same for any woman who might have to face this one day."
Yahoo
08-07-2025
- Entertainment
- Yahoo
Katie Thurston receives 'amazing' news amid breast cancer treatment
Katie Thurston just received good news amid her breast cancer journey. The "Bachelorette" alum, who first revealed she was diagnosed with breast cancer in February, said following a three-month treatment plan, her tumors are shrinking. "This is amazing news and I am so relieved!" she wrote on Instagram July 7. Thurston, 34, said that she will be on a treatment plan for life due to her metastatic, or stage 4, cancer diagnosis. In March, Thurston revealed that a recent PET scan detected spots on her liver, later confirming the cancer had spread. Stage 4 is defined by its spread "to a distant part of the body," per the National Cancer Institute. "There isn't a cure for breast cancer. But as long as funding for medical research continues, especially for #metavivors , then we have a chance at continuing a long healthy life," she added. 'I'm losing my memory': 'Bachelorette' star shares update on breast cancer battle Thurston said in February that she first grew concerned when she discovered a small lump in her breast during the summer of 2024. She would go on to receive a triple-positive breast cancer diagnosis, which is estrogen receptor-positive, progesterone receptor-positive and HER2 (human epithelial growth factor receptor 2)-positive. These hormones fuel cancer growth, and testing for these receptors helps determine treatment options. News of Thurston's diagnosis came five months after she got engaged to comedian Jeff Arcuri. The pair married earlier this year. Contributing: Saman Shafiq and KiMi Robinson This article originally appeared on USA TODAY: Katie Thurston cancer: 'Bachelorette' alum gives update
USA Today
08-07-2025
- Entertainment
- USA Today
Katie Thurston receives 'amazing' news amid breast cancer treatment
Katie Thurston just received good news amid her breast cancer journey. The "Bachelorette" alum, who first revealed she was diagnosed with breast cancer in February, said following a three-month treatment plan, her tumors are shrinking. "This is amazing news and I am so relieved!" she wrote on Instagram July 7. Thurston, 34, said that she will be on a treatment plan for life due to her metastatic, or stage 4, cancer diagnosis. In March, Thurston revealed that a recent PET scan detected spots on her liver, later confirming the cancer had spread. Stage 4 is defined by its spread "to a distant part of the body," per the National Cancer Institute. "There isn't a cure for breast cancer. But as long as funding for medical research continues, especially for #metavivors , then we have a chance at continuing a long healthy life," she added. 'I'm losing my memory': 'Bachelorette' star shares update on breast cancer battle Thurston said in February that she first grew concerned when she discovered a small lump in her breast during the summer of 2024. She would go on to receive a triple-positive breast cancer diagnosis, which is estrogen receptor-positive, progesterone receptor-positive and HER2 (human epithelial growth factor receptor 2)-positive. These hormones fuel cancer growth, and testing for these receptors helps determine treatment options. News of Thurston's diagnosis came five months after she got engaged to comedian Jeff Arcuri. The pair married earlier this year. Contributing: Saman Shafiq and KiMi Robinson
